Thyroid function and liver scarring in fatty liver disease
Part of Digestive system, Hormones & metabolism clinical trials.
This study looks at whether having an underactive thyroid (hypothyroidism) is linked to more severe liver scarring in people with fatty liver disease (MASLD). You may be asked to participate if you have fatty liver and either have hypothyroidism or a normal thyroid, to help doctors understand how these conditions are connected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You need a diagnosis of fatty liver disease (MASLD) found on an ultrasound, plus at least one related condition like being overweight, having type 2 diabetes, or high blood pressure.
- You either have an underactive thyroid (hypothyroidism) or a normal thyroid (as a control).
- You must have blood test results already available so the doctors can calculate your liver scarring risk.
- You cannot have hepatitis B or C, autoimmune liver disease, or other specific liver conditions.
- You cannot have severe kidney or heart failure, be pregnant, or currently breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether having an underactive thyroid (hypothyroidism) makes liver scarring worse in people with fatty liver disease. It uses simple blood tests and ultrasound to measure fibrosis without needing a biopsy.
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
This study aims to build a tool to predict how MASLD-related cirrhosis (fatty liver disease leading to liver scarring) will progress. It may help doctors and patients better understand the outlook and plan care.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
This study is testing whether an MRI can help doctors see liver scarring (fibrosis) in people with MASLD, a type of fatty liver disease. It is for patients who already need a liver biopsy as part of their care, to compare the MRI results with the biopsy.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.